Literature DB >> 29445533

Insomnia and cognitive behavioural therapy-how to assess your patient and why it should be a standard part of care.

Kirstie N Anderson1.   

Abstract

Hippocrates recognized the importance of asking about sleep as long ago as 400 BC when he wrote "sleep and watchfulness, both of them when immoderate, constitute disease". Disrupted sleep for any reason has immediate and long term consequences on physical and mental health. Insomnia disorder ("immoderate watchfulness") remains the commonest sleep disorder in primary and secondary care with an estimated 5-10% of the adult population affected. While it is commonly comorbid with other physical and mental health problems, the new diagnostic classification has been helpfully simplified such that it is considered a disorder in itself. If it is the patient's main concern, it warrants treatment. Patients and health professionals have often had limited teaching about effective strategies for insomnia which leaves many untreated and insomnia can be unfairly perceived as a challenging symptom to manage. The first line treatment is now well established as insomnia-specific cognitive behavioural therapy (CBTi) in the most recent US and European treatment guidelines. Over 25 years of high quality research have shown evidence for sustained improvements in sleep in those with insomnia alone or insomnia comorbid with other conditions. This is a simple CBT to deliver with better and safer outcomes than prescription hypnotics. Therefore, this review will cover the initial assessment of insomnia, including insomnia mimics, the selection of patients for treatment and the key components of CBT therapy. Finally, the review will cover evidence for different modes of delivery (online, self, help, group or individual face to face) in a variety of clinical settings.

Entities:  

Keywords:  Insomnia; cognitive behavioural therapy (CBT); hypnotics

Year:  2018        PMID: 29445533      PMCID: PMC5803038          DOI: 10.21037/jtd.2018.01.35

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  40 in total

1.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

2.  Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance.

Authors:  Richard P Allen; Daniel L Picchietti; Diego Garcia-Borreguero; William G Ondo; Arthur S Walters; John W Winkelman; Marco Zucconi; Raffaele Ferri; Claudia Trenkwalder; Hochang B Lee
Journal:  Sleep Med       Date:  2014-05-17       Impact factor: 3.492

Review 3.  Comparing MSLT and ESS in the measurement of excessive daytime sleepiness in obstructive sleep apnoea syndrome.

Authors:  S Y Y Fong; C K W Ho; Y K Wing
Journal:  J Psychosom Res       Date:  2005-01       Impact factor: 3.006

4.  European guideline for the diagnosis and treatment of insomnia.

Authors:  Dieter Riemann; Chiara Baglioni; Claudio Bassetti; Bjørn Bjorvatn; Leja Dolenc Groselj; Jason G Ellis; Colin A Espie; Diego Garcia-Borreguero; Michaela Gjerstad; Marta Gonçalves; Elisabeth Hertenstein; Markus Jansson-Fröjmark; Poul J Jennum; Damien Leger; Christoph Nissen; Liborio Parrino; Tiina Paunio; Dirk Pevernagie; Johan Verbraecken; Hans-Günter Weeß; Adam Wichniak; Irina Zavalko; Erna S Arnardottir; Oana-Claudia Deleanu; Barbara Strazisar; Marielle Zoetmulder; Kai Spiegelhalder
Journal:  J Sleep Res       Date:  2017-09-05       Impact factor: 3.981

5.  Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors.

Authors:  C M Morin; M LeBlanc; M Daley; J P Gregoire; C Mérette
Journal:  Sleep Med       Date:  2006-02-03       Impact factor: 3.492

Review 6.  Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies.

Authors:  Chiara Baglioni; Gemma Battagliese; Bernd Feige; Kai Spiegelhalder; Christoph Nissen; Ulrich Voderholzer; Caterina Lombardo; Dieter Riemann
Journal:  J Affect Disord       Date:  2011-02-05       Impact factor: 4.839

7.  Treating Acute Insomnia: A Randomized Controlled Trial of a "Single-Shot" of Cognitive Behavioral Therapy for Insomnia.

Authors:  Jason G Ellis; Toby Cushing; Anne Germain
Journal:  Sleep       Date:  2015-06-01       Impact factor: 5.849

Review 8.  Insomnia and comorbid psychiatric disorders.

Authors:  Dieter Riemann
Journal:  Sleep Med       Date:  2007-12       Impact factor: 3.492

9.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

10.  Co-occurring insomnia and obstructive sleep apnea.

Authors:  Kenneth L Lichstein; S Justin Thomas; Julie A Woosley; James D Geyer
Journal:  Sleep Med       Date:  2013-06-13       Impact factor: 3.492

View more
  4 in total

Review 1.  Sleep Monitoring in Athletes: Motivation, Methods, Miscalculations and Why it Matters.

Authors:  Shona L Halson
Journal:  Sports Med       Date:  2019-10       Impact factor: 11.136

2.  Internet-Delivered Cognitive Behavioral Therapy for Insomnia Comorbid With Chronic Pain: Randomized Controlled Trial.

Authors:  Tobias Wiklund; Peter Molander; Philip Lindner; Gerhard Andersson; Björn Gerdle; Elena Dragioti
Journal:  J Med Internet Res       Date:  2022-04-29       Impact factor: 7.076

3.  Sleep pattern and predictors of daily versus as-needed hypnotics use in middle-aged and older adults with insomnia.

Authors:  Maria Tanielian; Jumana Antoun; Munir Sidani; Ahmad Halabi; Malak Hoballah; Kegham Hawatian; Georges Assaf
Journal:  BMC Prim Care       Date:  2022-05-02

4.  The effects of cognitive behavioral therapy for insomnia in people with type 2 diabetes mellitus, pilot RCT part II: diabetes health outcomes.

Authors:  Mohammed M Alshehri; Shaima A Alothman; Aqeel M Alenazi; Jason L Rucker; Milind A Phadnis; John M Miles; Catherine F Siengsukon; Patricia M Kluding
Journal:  BMC Endocr Disord       Date:  2020-09-05       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.